0000886163-20-000027.txt : 20200227 0000886163-20-000027.hdr.sgml : 20200227 20200227203514 ACCESSION NUMBER: 0000886163-20-000027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200227 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FOEHR MATTHEW W CENTRAL INDEX KEY: 0001237556 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 20665163 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES RD #200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-02-27 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001237556 FOEHR MATTHEW W 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 0 1 0 0 President and COO Common Stock 2020-02-27 4 M 0 7225 14.47 A 160968 D Common Stock 2020-02-27 4 S 0 7225 110.0 D 153743 D Common Stock 2020-02-27 4 M 0 1706 21.92 A 155449 D Employee Stock Option (right to buy) 14.47 2020-02-27 2020-02-27 4 M 0 7225 0.0 D 2022-02-09 Common Stock 7225 7225 D Employee Stock Option (right to buy) 21.92 2020-02-27 2020-02-27 4 M 0 1706 0.0 D 2023-02-15 Common Stock 1706 66625 D The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. By: Charles S. Berkman For: Matthew W. Foehr 2020-02-27